Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase

A. Klinke, E. Berghausen, K. Friedrichs, S. Molz, D. Lau, L. Remane, M. Berlin, C. Kaltwasser, M. Adam, D. Mehrkens, M. Mollenhauer, K. Manchanda, T. Ravekes, GA. Heresi, M. Aytekin, RA. Dweik, JK. Hennigs, L. Kubala, E. Michaëlsson, S....

. 2018 ; 3 (11) : . [pub] 20180607

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19045424

Grant support
P01 HL076491 NHLBI NIH HHS - United States
P01 HL098055 NHLBI NIH HHS - United States
P01 HL103453 NHLBI NIH HHS - United States

Pulmonary arterial hypertension (PAH) remains a disease with limited therapeutic options and dismal prognosis. Despite its etiologic heterogeneity, the underlying unifying pathophysiology is characterized by increased vascular tone and adverse remodeling of the pulmonary circulation. Myeloperoxidase (MPO), an enzyme abundantly expressed in neutrophils, has potent vasoconstrictive and profibrotic properties, thus qualifying as a potential contributor to this disease. Here, we sought to investigate whether MPO is causally linked to the pathophysiology of PAH. Investigation of 2 independent clinical cohorts revealed that MPO plasma levels were elevated in subjects with PAH and predicted adverse outcome. Experimental analyses showed that, upon hypoxia, right ventricular pressure was less increased in Mpo-/- than in WT mice. The hypoxia-induced activation of the Rho-kinase pathway, a critical subcellular signaling pathway yielding vasoconstriction and structural vascular remodeling, was blunted in Mpo-/- mice. Mice subjected to i.v. infusion of MPO revealed activation of Rho-kinase and increased right ventricular pressure, which was prevented by coinfusion of the Rho-kinase inhibitor Y-27632. In the Sugen5416/hypoxia rat model, PAH was attenuated by the MPO inhibitor AZM198. The current data demonstrate a tight mechanistic link between MPO, the activation of Rho-kinase, and adverse pulmonary vascular function, thus pointing toward a potentially novel avenue of treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045424
003      
CZ-PrNML
005      
20200113082210.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1172/jci.insight.97530 $2 doi
035    __
$a (PubMed)29875311
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klinke, Anna $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany. International Clinical Research Center, Centre of Biomolecular and Cellular Engineering (CBCE), St. Anne's University Hospital Brno, Brno, Czech Republic.
245    10
$a Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase / $c A. Klinke, E. Berghausen, K. Friedrichs, S. Molz, D. Lau, L. Remane, M. Berlin, C. Kaltwasser, M. Adam, D. Mehrkens, M. Mollenhauer, K. Manchanda, T. Ravekes, GA. Heresi, M. Aytekin, RA. Dweik, JK. Hennigs, L. Kubala, E. Michaëlsson, S. Rosenkranz, TK. Rudolph, SL. Hazen, H. Klose, RT. Schermuly, V. Rudolph, S. Baldus,
520    9_
$a Pulmonary arterial hypertension (PAH) remains a disease with limited therapeutic options and dismal prognosis. Despite its etiologic heterogeneity, the underlying unifying pathophysiology is characterized by increased vascular tone and adverse remodeling of the pulmonary circulation. Myeloperoxidase (MPO), an enzyme abundantly expressed in neutrophils, has potent vasoconstrictive and profibrotic properties, thus qualifying as a potential contributor to this disease. Here, we sought to investigate whether MPO is causally linked to the pathophysiology of PAH. Investigation of 2 independent clinical cohorts revealed that MPO plasma levels were elevated in subjects with PAH and predicted adverse outcome. Experimental analyses showed that, upon hypoxia, right ventricular pressure was less increased in Mpo-/- than in WT mice. The hypoxia-induced activation of the Rho-kinase pathway, a critical subcellular signaling pathway yielding vasoconstriction and structural vascular remodeling, was blunted in Mpo-/- mice. Mice subjected to i.v. infusion of MPO revealed activation of Rho-kinase and increased right ventricular pressure, which was prevented by coinfusion of the Rho-kinase inhibitor Y-27632. In the Sugen5416/hypoxia rat model, PAH was attenuated by the MPO inhibitor AZM198. The current data demonstrate a tight mechanistic link between MPO, the activation of Rho-kinase, and adverse pulmonary vascular function, thus pointing toward a potentially novel avenue of treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a amidy $x aplikace a dávkování $7 D000577
650    _2
$a zvířata $7 D000818
650    _2
$a kohortové studie $7 D015331
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x krev $x mortalita $x patologie $x patofyziologie $7 D006976
650    _2
$a hypoxie $x krev $x etiologie $x patologie $7 D000860
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a plíce $x patologie $7 D008168
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a lidé středního věku $7 D008875
650    _2
$a peroxidasa $x aplikace a dávkování $x krev $x metabolismus $7 D009195
650    _2
$a arteria pulmonalis $x patologie $x patofyziologie $7 D011651
650    _2
$a pyridiny $x aplikace a dávkování $7 D011725
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $x krev $x metabolismus $7 D011994
650    _2
$a remodelace cév $x účinky léků $x fyziologie $7 D066253
650    _2
$a vazokonstrikce $x účinky léků $x fyziologie $7 D014661
650    _2
$a kinázy asociované s rho $x antagonisté a inhibitory $x metabolismus $7 D054460
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Berghausen, Eva $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Friedrichs, Kai $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Molz, Simon $u University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Lau, Denise $u University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Remane, Lisa $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Berlin, Matthias $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Kaltwasser, Charlotte $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Adam, Matti $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Mehrkens, Dennis $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Mollenhauer, Martin $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Manchanda, Kashish $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Ravekes, Thorben $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Heresi, Gustavo A $u Pulmonary and Critical Care Medicine, Respiratory Institute, and.
700    1_
$a Aytekin, Metin $u Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
700    1_
$a Dweik, Raed A $u Pulmonary and Critical Care Medicine, Respiratory Institute, and.
700    1_
$a Hennigs, Jan K $u Cardiovascular Institute, Stanford University, School of Medicine, Stanford, California, USA. Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Kubala, Lukas $u International Clinical Research Center, Centre of Biomolecular and Cellular Engineering (CBCE), St. Anne's University Hospital Brno, Brno, Czech Republic. Institute of Biophysics, Czech Academy of Sciences, Brno, Czech Republic.
700    1_
$a Michaëlsson, Erik $u Bioscience Heart Failure, Cardiovascular, Renal and Metabolism, Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca, Gothenburg, Sweden.
700    1_
$a Rosenkranz, Stephan $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Rudolph, Tanja K $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Hazen, Stanley L $u Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
700    1_
$a Klose, Hans $u Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Schermuly, Ralph T $u Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany.
700    1_
$a Rudolph, Volker $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
700    1_
$a Baldus, Stephan $u Heart Center, Department of Cardiology. Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany.
773    0_
$w MED00194017 $t JCI insight $x 2379-3708 $g Roč. 3, č. 11 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29875311 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082541 $b ABA008
999    __
$a ok $b bmc $g 1483693 $s 1084097
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 3 $c 11 $e 20180607 $i 2379-3708 $m JCI insight $n JCI Insight $x MED00194017
GRA    __
$a P01 HL076491 $p NHLBI NIH HHS $2 United States
GRA    __
$a P01 HL098055 $p NHLBI NIH HHS $2 United States
GRA    __
$a P01 HL103453 $p NHLBI NIH HHS $2 United States
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options